Evotec receives € 3 million payment from Sanofi
Evotec achieves third milestone in cell therapy diabetes alliance with Sanofi
Evotec SE announced successful achievement of a third milestone in their diabetes research alliance with Sanofi (“TargetBCD”), resulting in a payment of € 3 m to Evotec.
This milestone was triggered after Evotec met pre-agreed critical criteria within the beta cell replacement therapy programme. The ultimate goal of the collaboration is to develop a beta cell replacement therapy for people with diabetes based on beta cells derived from human induced pluripotent stem cells.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are extremely pleased with the progress we are making on this beta cell therapy approach which has the potential to restore beta cell function and, thereby, address the root cause of diabetes rather than only its symptoms.”
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Category:Antithyroid_drugs
BioServices: Marketplace for service providers in the pharmaceuticals and biotech industry - “Speed Dating” to increase networking effectiveness

Sartopure® PP3 | Prefilters | Sartorius

Swiss biotechnology startup HAYA Therapeutics announces collaboration with Lilly - Discovery of novel regulatory genomic targets for obesity and related metabolic conditions using proprietary RNA platform
Spin-off supports Dutch and Belgian health organizations in monitoring COVID-19

Could leaky blood vessels in the brain be a culprit in Alzheimer’s disease? - A promising new approach to treating Alzheimer’s disease and other dementias
Phase 2a Study of HIV-1 Investigational Maturation Inhibitor - Demonstration of positive results for therapy designed to attack virus in a new way
